Barclays PLC Adverum Biotechnologies, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.81 - $1.34 $11,424 - $18,899
-14,104 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$1.23 - $1.95 $112,353 - $178,120
-91,344 Reduced 86.62%
14,104 $18,000
Q4 2021

Feb 14, 2022
BUY
$1.74 - $2.4 $97,687 - $134,740
56,142 Added 113.86%
105,448 $185,000
Q3 2021

Nov 09, 2021
SELL
$2.08 - $3.6 $20,136 - $34,851
-9,681 Reduced 16.41%
49,306 $107,000
Q2 2021

Aug 13, 2021
SELL
$3.36 - $10.56 $404,070 - $1.27 Million
-120,259 Reduced 67.09%
58,987 $207,000
Q1 2021

May 13, 2021
SELL
$9.26 - $14.36 $1.07 Million - $1.66 Million
-115,536 Reduced 39.19%
179,246 $1.77 Million
Q4 2020

Feb 11, 2021
SELL
$9.84 - $14.26 $996,231 - $1.44 Million
-101,243 Reduced 25.56%
294,782 $3.19 Million
Q3 2020

Nov 12, 2020
BUY
$10.3 - $21.64 $1.17 Million - $2.45 Million
113,205 Added 40.03%
396,025 $4.08 Million
Q2 2020

Aug 12, 2020
BUY
$8.53 - $25.64 $120,605 - $362,523
14,139 Added 5.26%
282,820 $5.91 Million
Q1 2020

May 13, 2020
SELL
$7.98 - $16.32 $1.55 Million - $3.18 Million
-194,557 Reduced 42.0%
268,681 $2.63 Million
Q4 2019

Feb 10, 2020
BUY
$5.12 - $12.22 $2.14 Million - $5.11 Million
418,137 Added 927.11%
463,238 $5.34 Million
Q3 2019

Nov 14, 2019
SELL
$5.24 - $15.89 $77,441 - $234,838
-14,779 Reduced 24.68%
45,101 $246,000
Q2 2019

Aug 14, 2019
BUY
$5.1 - $11.89 $55,054 - $128,352
10,795 Added 21.99%
59,880 $711,000
Q1 2019

May 15, 2019
BUY
$3.03 - $6.02 $94,620 - $187,992
31,228 Added 174.88%
49,085 $258,000
Q4 2018

Feb 14, 2019
SELL
$2.87 - $5.92 $147,167 - $303,565
-51,278 Reduced 74.17%
17,857 $56,000
Q3 2018

Nov 14, 2018
BUY
$4.5 - $7.6 $211,369 - $356,979
46,971 Added 211.92%
69,135 $418,000
Q2 2018

Aug 14, 2018
SELL
$5.3 - $6.9 $390,710 - $508,661
-73,719 Reduced 76.88%
22,164 $117,000
Q1 2018

May 15, 2018
BUY
$3.65 - $7.95 $224,248 - $488,432
61,438 Added 178.37%
95,883 $556,000
Q4 2017

Feb 14, 2018
BUY
$2.85 - $3.95 $85,500 - $118,500
30,000 Added 674.92%
34,445 $120,000
Q3 2017

Nov 14, 2017
BUY
$2.45 - $3.65 $10,890 - $16,224
4,445
4,445 $16,000

Others Institutions Holding ADVM

# of Institutions
3
Shares Held
524K
Call Options Held
0
Put Options Held
0
View Full List

About Adverum Biotechnologies, Inc.

ADVM Quotes by TradingView
  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email